Human Papillomavirus Vaccine (HPV) Market to Reach $10.8 Bn, Globally, by 2031 at 12.4% CAGR: Allied Market Research

Increase in the prevalence of HPV-related diseases drives the growth of the global human papillomavirus vaccine market.

PORTLAND, Ore., July 21, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Human Papillomavirus Vaccine (HPV) Market by By Type (Tetravalent, Nonavalent, Bivalent), by By Disease Indication (Cervical Cancer, Anal Cancer, Vulvar & Vaginal Cancer, Penile Cancer, Oropharyngeal Cancer, Others), by By Industry Vertical (Public and Private Alliances, Government Entities, Physicians, Others): Global Opportunity Analysis and Industry Forecast, 2021-2030." According to the report, the global human papillomavirus vaccine market was estimated at $3.9 billion in 2021, and is anticipated to hit $10.8 billion by 2030, registering a CAGR of 12.4% from 2022 to 2030.

Download Report (245 Pages PDF with Insights, Charts, Tables, Figures): https://www.alliedmarketresearch.com/request-sample/14697

Prime determinants for growth-

Increase in the prevalence of HPV-related diseases drives the growth of the global human papillomavirus vaccine market. At the same time, rise in government expenditure on HPV vaccination programs has supplemented the market growth even more. Moreover, adequate increases in production capacity is expected to create lucrative opportunities in the industry.

Covid-19 scenario-

• Ever since the Covid-19 pandemic has broken out, vaccine producers and other scientists have been continuously working on the development of HPV vaccines as well as COVID-19 viral symptoms, which has impacted the global papillomavirus vaccine market positively.
• Even during the lockdown and the government controls set in response to the pandemic, most healthcare personnel were seen to carry out their tasks, and companies were also spending heavily on vaccine development.

 Scope of the Report: -

The tetravalent segment to maintain the lion's share-

Based on type, the tetravalent segment accounted for more than three-fourths of the global human papillomavirus vaccine market share in 2021, and is anticipated to rule the roost by 2030. This is because the tetravalent human papillomavirus vaccine protects against HPV types 6, 11, 16, and 18 infections. The nonavalent segment, however, would cite the fastest CAGR of 13.9% throughout the forecast period.

Specific Requirement on COVID-19? Ask to Our Industry Expert: https://www.alliedmarketresearch.com/request-for-customization/14697?reqfor=covid

The public and private alliances segment to lead the trail-

Based on industry vertical, the public and private alliances segment held around two-fifths of the global human papillomavirus vaccine market revenue in 2021, and is expected to lead the trail by 2030. Various organizations and institutions, such as GAVI, are also attempting to improve vaccine use in disadvantaged countries by providing low-cost vaccines. As a result, these countries are significant growth hotspots in the vaccine market. These factors propel the segment's growth. The government entities segment, on the other hand, would manifest the fastest CAGR of 12.8% from 2021 to 2030.

North America to dominate by 2030-

Based on region, North America, held the major share in 2021, generating more than two-fifths of the global human papillomavirus vaccine market. Initiatives taken by the government for treating people infected with the human papilloma virus are predicted to be the major driving factor for the market. At the same time, the market across Asia-Pacific would grow at the fastest CAGR of 14.2% by 2030.

Prominent market players-

• Johnson & Johnson
• Merck & Co., Inc.
• AstraZeneca Plc
• Novartis AG
• Serum Institute of India Pvt. Ltd.
• GlaxoSmithKline Plc
• Sanofi S.A.
• Bharat Biotech
• Inovio Pharmaceuticals, Inc.
• Xenetic Biosciences, Inc.

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the human papillomavirus vaccine market share, segments, current trends, estimations, and dynamics along with human papillomavirus vaccine market analysis from 2021 to 2030 to identify the prevailing HPV vaccine market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis assists to determine the prevailing the human papillomavirus vaccine market growth and market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global HPV vaccine market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global human papillomavirus vaccine market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

• By By Type
• Tetravalent
• Nonavalent
• Bivalent
• By By Disease Indication
• Cervical Cancer
• Anal Cancer
• Vulvar & Vaginal Cancer
• Penile Cancer
• Oropharyngeal Cancer
• Others
• By Industry Vertical
• Public and Private Alliances
• Government Entities
• Physicians
• Others
• By Region
• North America
• U.S. Human Papillomavirus Vaccine (HPV) Market
• Canada Human Papillomavirus Vaccine (HPV) Market
• Mexico Human Papillomavirus Vaccine (HPV) Market
• Europe
• Germany Human Papillomavirus Vaccine (HPV) Market
• United Kingdom Human Papillomavirus Vaccine (HPV) Market
• France Human Papillomavirus Vaccine (HPV) Market
• Spain Human Papillomavirus Vaccine (HPV) Market
• Italy Human Papillomavirus Vaccine (HPV) Market
• Rest of Europe
• Asia-Pacific
• China Human Papillomavirus Vaccine (HPV) Market
• Japan Human Papillomavirus Vaccine (HPV) Market
• India Human Papillomavirus Vaccine (HPV) Market
• South Korea Human Papillomavirus Vaccine (HPV) Market
• Australia Human Papillomavirus Vaccine (HPV) Market
• Rest of Asia-Pacific
• LAMEA
• Brazil Human Papillomavirus Vaccine (HPV) Market
• Saudi Arabia Human Papillomavirus Vaccine (HPV) Market
• United Arab Emirates Human Papillomavirus Vaccine (HPV) Market
• South Africa Human Papillomavirus Vaccine (HPV) Market
• Rest of LAMEA

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Request for 14 days free trial: https://www.alliedmarketresearch.com/avenue/trial/starter

"We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market."

Trending Reports in Healthcare Industry (Book Now with 10% Discount + Covid-19 scenario):

The global Vaccines Market size accounted for $38,061.15 Million in 2021, and is expected to reach $72,129.61 Million by 2031, registering a CAGR of 6.6% from 2022 to 2031.

The global Cancer Vaccines Market was valued at $4,188 million in 2019, and is projected to reach $7,303 million by 2027, registering a CAGR of 12.6% from 2020 to 2027.

The global Animal Vaccines Market size was valued at $9,093.9 million in 2020, and is projected to reach $15,201.5 million by 2030, registering a CAGR of 5.2% from 2021 to 2030.

The global DNA Vaccine Market size was valued at $422.77 Million in 2020 and is projected to reach $774.43 Million by 2030 registering a CAGR of 6.3% from 2021 to 2030.

The global Meningococcal Vaccine Market size was valued at $1,935.5 million in 2018, and is projected to reach $4,192.6 million by 2026, registering a CAGR of 9.5% from 2019 to 2026.

The global Conjugate Vaccines Market - Opportunity Analysis and Industry Forecast, 2022-2029

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com/reports-store/life-sciences
Follow Us on LinkedIn: https://www.linkedin.com/showcase/life-sciences-industry-research/

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg